ADMS - Adamas Pharmaceuticals Inc


Weak GrowthEarnings/Profit is Negative


based on last 5 year data.
Income Statement is WEAK
Revenue Growth is 26.35%
Operating Income is Negative but improving
Net Income is Negative
Earnings Per Share (EPS) is Negative but improving
Net Margin is -71.11%
Balance Sheet is WEAK
Current Asset to Current Liability Ratio is 4.53
Debt Ratio is 1.15
Current Debt to Net Income Ratio not available
Total Debt to Total Assets Ratio is 0.9
Cash Flow is WEAK
Cash from Operations is Negative but improving
Capital Expenditure not available
Net Increase in Cash is Positive
Long Term Score Trend is POSITIVE
Investment Risk is High
based on last 4 quarter data.
Unless specified, all values are in USD Millions. Data extracted from SEC Filing and are subject to processing and input errors.
Adamas Pharmaceuticals Inc (ADMS) -
Adamas Pharmaceuticals Inc. delivers innovative medicines that reduce the burden of neurological diseases on patients, caregivers and society. The company is a fully integrated company focused on growing a portfolio of therapies to address a range of neurological diseases.
Exchange - NASDAQ
Industry - Pharmaceutical Preparation Manufacturing
Sector - Manufacturing
CEO - Neil McFarlane
Employees - 138

Disclaimer - Investment in securities involves substantial risk and could result in significant loss. It is not suitable for every investor. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser. We may own some of the securities mentioned in this website.
Know the Stock © 2021 and future.